These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 7435247)

  • 41. Lercanidipine vs lacidipine in isolated systolic hypertension.
    Millar-Craig M; Shaffu B; Greenough A; Mitchell L; McDonald C
    J Hum Hypertens; 2003 Nov; 17(11):799-806. PubMed ID: 14578921
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and tolerability of two formulations of ramipril in Korean adults with mild to moderate essential hypertension: an 8-week, multicenter, prospective, randomized, open-label, parallel-group noninferiority trial.
    Kim SH; Chung WY; Zo JH; Kim MA; Chang HJ; Cho YS; Youn TJ; Chae IH; Choi DJ; Gwak JJ; Lee HY; Park JS; Kang HJ; Kim YJ; Kim HS
    Clin Ther; 2009 May; 31(5):988-98. PubMed ID: 19539099
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].
    Trinquand C; Romanet JP; Nordmann JP; Allaire C;
    J Fr Ophtalmol; 2003 Feb; 26(2):131-6. PubMed ID: 12660585
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
    Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
    Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release results of the Metoprolol Succinate-Felodipine Antihypertension Combination Trial (M-FACT).
    Frishman WH; Hainer JW; Sugg J;
    Am J Hypertens; 2006 Apr; 19(4):388-95. PubMed ID: 16580575
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clonidine twice daily in hypertension. Effects of two dosage regimens on blood pressure, side-effects and plasma clonidine concentrations.
    Lilja M; Huikuri H; Jounela AJ; Juustila HJ; Paalzow G
    Acta Med Scand; 1983; 214(2):111-7. PubMed ID: 6353878
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Diltiazem 180 mg in delayed release formulation in mild and moderate arterial hypertension].
    Serra-Pinto L; Baptista A; Rocha E
    Rev Port Cardiol; 1995 Apr; 14(4):303-10, 283-4. PubMed ID: 7612279
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Slow-release hydralazine in the treatment of essential arterial hypertension].
    Moscovici H; Yasbeck Júnior P; Fadul Neto J
    Arq Bras Cardiol; 1982 Sep; 39(3):197-9. PubMed ID: 7186366
    [No Abstract]   [Full Text] [Related]  

  • 49. Hydrallazine with beta-blocker and diuretic in the treatment of hypertension. A double-blind crossover study.
    Kalowski S; Hua AS; Whitworth JA; Kincaid-Smith P
    Med J Aust; 1979 Oct; 2(8):439-40. PubMed ID: 318493
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of a slow release formulation of oxprenolol with conventional oxprenolol in the treatment of hypertension.
    O'Brien KP; Stephens EJ
    N Z Med J; 1976 Aug; 84(570):142-4. PubMed ID: 1069924
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension.
    Spinasse LB; Santos AR; Suffys PN; Muxfeldt ES; Salles GF
    Pharmacogenomics; 2014 Feb; 15(2):169-78. PubMed ID: 24444407
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist.
    Andrén L; Svensson A; Dahlöf B; Eggertsen R; Hansson L
    Acta Med Scand; 1983; 214(2):125-30. PubMed ID: 6353879
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of prazosin with hydralazine in patients receiving hydrochlorothiazide. A randomized, double-blind clinical trial.
    Circulation; 1981 Oct; 64(4):772-9. PubMed ID: 7023744
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hydralazine slow-release: observations on serum profile and clinical efficacy in man.
    Talseth T; Fauchald P; Pape JF
    Curr Ther Res Clin Exp; 1977 Feb; 21(2):157-68. PubMed ID: 403050
    [No Abstract]   [Full Text] [Related]  

  • 55. Utilization of hydralazine or alpha-methyldopa for the management of early puerperal hypertension.
    Griffis KR; Martin JN; Palmer SM; Martin RW; Morrison JC
    Am J Perinatol; 1989 Oct; 6(4):437-41. PubMed ID: 2789542
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Use of intravenous hydralazine in treatment of hypertensive crisis].
    Cesar LA; Amato R; Pfeferman E; Serrano CV; Ramires JA; Bellotti G; Pileggi F
    Arq Bras Cardiol; 1991 May; 56(5):381-3. PubMed ID: 1823736
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of antihypertensive efficacy: propranolol versus oxprenolol in accelerated hypertension.
    Fernandez PG; Sharma JN; Galway AB; Kim BK; Granter S; Zachariah PK
    Pharmatherapeutica; 1982; 3(3):153-6. PubMed ID: 6752962
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative efficacy and safety of immediate-release and controlled-release hydralazine in black hypertensive patients.
    Adir J; Janda SM; Curry CL; Taylor RE; Poku CD; Rotenberg KS
    Clin Ther; 1987; 9(6):640-50. PubMed ID: 3326679
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination therapy of essential hypertension with pindolol (Visken) and hydralazine.
    Persson I
    Adv Clin Pharmacol; 1976; 11():1114-8. PubMed ID: 802071
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Treatment of arterial hypertension with the combination of hydralazine and propranolol].
    Sabbaga E; Chocair PR; Ianhez LE; Massola VC
    Rev Paul Med; 1974 Mar; 83(3):97-100. PubMed ID: 4445689
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.